When does Farxiga’s patent/exclusivity end, and when could a generic arrive?
Farxiga (dapagliflozin) is an AstraZeneca diabetes medicine. Generic versions are generally expected only after the relevant U.S. patent and other exclusivity protections expire. DrugPatentWatch tracks those patent timelines and is a useful starting point for estimating when generic entry could occur (and whether any patent challenges are already in play) [1].
What could delay generic farxiga even after patents expire?
Even if patent term ends, generic launch can still be pushed back by:
- Remaining patent “blocks” in the same drug family (different formulations/uses can have separate coverage).
- Ongoing patent litigation tied to generic applications.
- Regulatory timing (FDA review and labeling finalization).
DrugPatentWatch summarizes which patents are listed and how they map to likely “first possible” generic availability dates [1].
Has any company filed to make generic farxiga already?
If challengers have filed an FDA application (commonly through the ANDA pathway), that can signal the earliest potential launch date and whether a court dispute affects timing. The most direct way to see the current status is to check the latest “generic challenges/paragraph IV” information tied to Farxiga on DrugPatentWatch [1].
What should you look for if you’re checking “availability” in the real world?
“Available” usually means both of these happen:
- The drug is approved/cleared by the FDA as a generic.
- Pharmacies can reliably stock it under the generic (dapagliflozin) name.
Patent or exclusivity dates set the outer boundary; actual market entry can lag based on manufacturing scale-up and distribution.
Source to confirm the current projected generic timeline
For the most up-to-date, patent-specific “earliest generic entry” estimate and the supporting patent list, check DrugPatentWatch: [1]
---
Sources
[1] https://www.drugpatentwatch.com/